ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.95459
-0.17%
Brent Oil
83.605
0.58%
Bitcoin
65,353.04
2.12%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Pharvaris NV (PHVS)

  7. Pharvaris NV (PHVS) Noticias

PHVS Pharvaris NV

22.60
0.00 (0.00%)
Pre Mercado
Última actualización: 03:09:39
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Pharvaris NV PHVS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 22.60 03:09:39
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
22.60
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
10/4/202415:10GLOBEPharvaris Reports Fourth Quarter and Full Year 2023..
10/4/202415:08GLOBEPharvaris Appoints David Nassif, J.D., as Chief Financial..
04/4/202405:50GLOBEPharvaris to Present Deucrictibant Clinical Data at the CIIC..
18/3/202405:50GLOBEPharvaris Announces Phase 3 Clinical Study Design for..
11/3/202412:51EDGAR2Form 144 - Report of proposed sale of securities
06/3/202415:40EDGAR2Form F-3ASR - Automatic shelf registration statement of..
06/3/202415:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/3/202405:50GLOBEPharvaris to Present Deucrictibant Clinical Data at Upcoming..
05/3/202405:50GLOBEPharvaris to Participate in the Leerink Global Biopharma..
22/2/202405:50GLOBEPositive Results from CHAPTER-1 Phase 2 Study of..
16/2/202405:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/2/202405:50GLOBEPharvaris Announces Extraordinary Meeting of Shareholders
07/2/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202415:46EDGAR2Form 144 - Report of proposed sale of securities
26/1/202405:50GLOBEPharvaris to Present at the WSAAI Annual Meeting 2024
22/1/202406:35DJNPharvaris Says FDA Lifted Clinical Hold on Application for..
22/1/202405:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/1/202405:50GLOBEPharvaris Announces FDA Lifting of the Clinical Hold of..
08/1/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202405:50GLOBEPharvaris Provides Business Update and Outlines 2024..
02/1/202415:29EDGAR2Form 144 - Report of proposed sale of securities
08/12/202317:00GLOBEPharvaris Presents Deucrictibant Clinical Data and Analysis..
08/12/202315:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/12/202315:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/12/202315:36EDGAR2Form 144 - Report of proposed sale of securities
06/12/202306:08EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
06/12/202306:02GLOBEPharvaris Announces Pricing of $300 Million Underwritten..
06/12/202305:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/12/202305:50GLOBEPharvaris Announces Positive Top-line Phase 2 Data from the..
30/11/202305:50GLOBEPharvaris to Present at the GA²LEN UCARE Conference 2023
15/11/202305:50GLOBEPharvaris Appoints Stefan Abele, Ph.D., as Chief Technical..
09/11/202310:00GLOBEPharvaris Presents Deucrictibant Clinical Data and..
02/11/202305:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202305:50GLOBEPharvaris Reports Third Quarter 2023 Financial Results and..
30/10/202305:50GLOBEPharvaris To Present at the ACAAI 2023 Annual Scientific..
13/10/202305:50GLOBEPharvaris To Present at the APAAACI 2023 International..
04/10/202306:34GLOBEPharvaris To Present at the CIIC Fall 2023 Conference
19/9/202315:23EDGAR2Form 144 - Report of proposed sale of securities
19/9/202305:50GLOBEPharvaris To Participate in the 2023 Cantor Global..
06/9/202305:51GLOBEPharvaris To Present at the 18th German Allergy Congress
06/9/202305:50GLOBEPharvaris To Participate in the Morgan Stanley 21st Annual..
01/9/202317:02EDGAR2Form 144 - Report of proposed sale of securities
24/8/202315:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/8/202305:50GLOBEPharvaris To Present at the 2023 HAEi Regional Conference..
16/8/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
09/8/202318:00EDGAR2Form 144 - Report of proposed sale of securities
09/8/202317:38EDGAR2Form 144 - Report of proposed sale of securities
07/8/202309:16EDGAR2Form F-3 - Registration statement by foreign private issuers
07/8/202305:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202305:50GLOBEPharvaris Reports Second Quarter 2023 Financial Results and..

Su Consulta Reciente

NASDAQ
PHVS
Pharvaris NV
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados